Plain-English translation of NCT04899908 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called alongside radiation therapy for brain metastases—tumors that have spread to the brain from cancer in other parts of the body. The nanoparticles are tiny particles linked to gadolinium (a contrast substance often used in MRI scans) that may help radiation therapy work more effectively. You would be randomly assigned to receive either radiation plus the medication or radiation plus a placebo (a dummy treatment with no active ingredient).
Brain tumors that have spread from other cancers often come back even after radiation therapy. Researchers believe this medication might help radiation work better and reduce the chance of tumors returning in the same spot.
You likely qualify if…
You likely don't qualify if…
You would receive the study medication or placebo through an injection into a vein, starting 3–5 days before your radiation therapy begins. You will then receive the medication (or placebo) again during your radiation treatment—either once if radiation is a single session, or twice if radiation spans 5–6 days. Throughout the study, you'll have screening visits, treatment visits, and follow-up appointments with imaging scans and medical evaluations to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States